SEC Company Response from SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Sep 28, 2016
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: Sept. 28, 2016 · CIK: 0001390478 · Accession: 0001193125-16-723708
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-213493
Referenced dates: September 21, 2016
Letter
VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Re: Galena Biopharma, Inc. Registration Statement on Form S-3 File No. 333-213493
Dear Ms. Hayes:
On behalf of Galena Biopharma, Inc. (the “Company”), this letter will respond to your comment letter dated September 21, 2016 with respect to the above-referenced registration statement (the “Comment Letter”). Enclosed herewith for filing via Edgar is the Company’s Amendment No. 1 to the Registration Statement on Form S-3 (the “Registration Statement”).
The following response corresponds to the numbered comments contained in the Comment Letter, as follows:
1. Please update this section to incorporate by reference your Current Report on Form 8-K filed on August 12, 2016.
Response: The Company has revised the Registration Statement to incorporate the referenced Form 8-K.
* * *
On behalf of the Company, the undersigned hereby acknowledges the following:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
Ms. Suzanne Hayes
U.S. Securities and Exchange Commission
September 28, 2016
Page 2
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact the undersigned at (925) 498-7734 if you have any questions with respect to the responses contained in this letter or the Registration Statement.
Sincerely,
/s/ Thomas J. Knapp
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
GALENA BIOPHARMA, INC.
2000 Crow Canyon Place, Suite 380
San Ramon, CA 94583
September 28, 2016
VIA EDGAR TRANSMISSION
Ms. Suzanne Hayes
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re:
Galena Biopharma, Inc.
Registration Statement on Form S-3
File No. 333-213493
Dear Ms. Hayes:
On behalf of Galena Biopharma, Inc. (the “Company”), this letter will respond to your comment letter dated September 21, 2016 with
respect to the above-referenced registration statement (the “Comment Letter”). Enclosed herewith for filing via Edgar is the Company’s Amendment No. 1 to the Registration Statement on Form S-3 (the “Registration
Statement”).
The following response corresponds to the numbered comments contained in the Comment Letter, as follows:
1.
Please update this section to incorporate by reference your Current Report on Form 8-K filed on August 12, 2016.
Response: The Company has revised the Registration Statement to incorporate the referenced Form 8-K.
* * *
On behalf of the Company, the undersigned hereby acknowledges the following:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
Ms. Suzanne Hayes
U.S. Securities and Exchange Commission
September 28, 2016
Page 2
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the
disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact the undersigned at (925) 498-7734 if you have any questions with respect to the responses contained in this
letter or the Registration Statement.
Sincerely,
/s/ Thomas J. Knapp
Thomas J. Knapp
Interim General Counsel and
Corporate Secretary
cc:
Dr. Mark W. Schwartz, Ph.D.
Mr. John T. Burns
Mr. Christopher J. Melsha, Esq.